232 related articles for article (PubMed ID: 23274778)
1. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
[TBL] [Abstract][Full Text] [Related]
3. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.
Goto T; Takano M; Watanabe A; Miyamoto M; Kato M; Hirata J; Sasa H; Furuya K
Int J Gynecol Cancer; 2011 Feb; 21(2):263-8. PubMed ID: 21270609
[TBL] [Abstract][Full Text] [Related]
4. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.
Chang C; Chiang AJ; Wang HC; Chen WA; Chen J
Ann Surg Oncol; 2015 Nov; 22(12):3976-80. PubMed ID: 25777089
[TBL] [Abstract][Full Text] [Related]
6. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
7. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Mi D; Zhang Y
Arch Gynecol Obstet; 2020 Mar; 301(3):779-785. PubMed ID: 32034508
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
10. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
[TBL] [Abstract][Full Text] [Related]
11. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
[TBL] [Abstract][Full Text] [Related]
12. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
13. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
14. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
[TBL] [Abstract][Full Text] [Related]
16. Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.
Krell D; Said Battistino F; Benafif S; Ganegoda L; Hall M; Rustin GJS
Int J Gynecol Cancer; 2017 Jul; 27(6):1118-1122. PubMed ID: 28333841
[TBL] [Abstract][Full Text] [Related]
17. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
18. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
[TBL] [Abstract][Full Text] [Related]
19. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
20. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]